story of the week
Durable Complete Response in HER2-Positive Breast Cancer Following Trastuzumab Discontinuation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durable Complete Response in HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
Breast Cancer Res Treat 2017 Sep 11;[EPub Ahead of Print], N Niikura, A Shimomura, Y Fukatsu, M Sawaki, R Ogiya, H Yasojima, T Fujisawa, M Yamamoto, M Tsuneizumi, A Kitani, J Watanabe, A Matsui, Y Takahashi, S Takashima, T Shien, K Tamura, S Saji, N Masuda, Y Tokuda, H IwataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.